Status:
RECRUITING
Development and Application of a Thrombosis Risk Prediction Model in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors
Lead Sponsor:
Beijing Chao Yang Hospital
Collaborating Sponsors:
Capital Medical University
China-Japan Friendship Hospital
Conditions:
Lung Cancer
Venous Thromboembolism
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this observational study is to explore the incidence, risk factors, and relationship with therapeutic outcomes of VTE (venous thromboembolism) and ATE (arterial thromboembolism) associa...
Eligibility Criteria
Inclusion
- Age ≥18 years
- Histopathologically confirmed lung cancer diagnosis at enrollment
- Received at least one dose of a China-approved lung cancer immune checkpoint inhibitor
- Signed informed consent form
Exclusion
- Excluded based on inclusion criteria
- Cannot comply with follow-up requirements
Key Trial Info
Start Date :
January 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2027
Estimated Enrollment :
2400 Patients enrolled
Trial Details
Trial ID
NCT06950697
Start Date
January 1 2019
End Date
December 1 2027
Last Update
April 30 2025
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
2
The Fourth Hospital of Inner Mongolia Autonomous Region
Hohhot, Inner Mongolia, China
3
Beijing Chaoyang Hospital, Capital Medical University
Beijing, China
4
Beijing Luhe Hospital, Capital Medical University
Beijing, China